Journal of Practical Oncology ›› 2024, Vol. 38 ›› Issue (2): 112-120.doi: 10.11904/j.issn.1002-3070.2024.02.006

• Clinical Research • Previous Articles     Next Articles

A Meta-analysis of the clinical efficacy of hepatic arterial chemoembolization combined with second-stage surgical resection and hepatic arterial chemoembolization alone for unresectable intermediate and advanced liver cancer in Chinese population

HOU Mingxing, WEI Yonggang   

  1. Division of Liver Surgery,Department of General Surgery,West China Hospital,Sichuan University,Chengdu 610000,China
  • Received:2022-12-26 Revised:2023-03-08 Online:2024-04-28 Published:2024-07-12

Abstract: Objective The aim of this study was to compare the clinical efficacy of hepatic artery chemoembolization combined with two-stage surgical resection and simple hepatic arterial chemoembolization in the treatment of unresectable advanced liver cancer in the Chinese population. Methods A clinical controlled study literature was collected in China through computer and manual retrieval on the combination of hepatic arterial chemoembolization with two-stage surgery and hepatic arterial chemoembolization alone for the treatment of unresectable liver cancer.A Meta-analysis was conducted on 17 experiments that met the inclusion criteria using Revman 5.2 software and applying heterogeneity test analysis. Results Compared with the combination of hepatic artery chemoembolization and phase II surgery,simple hepatic arterial chemoembolization had higher postoperative 1-year,2-year and 3-year risk of death (OR=2.82,2.22 and 3.40,P<0.05).In addition,under the same conditions of chemoembolization drugs,compared with the combination of hepatic arterial chemoembolization and phase II s,simple hepatic arterial chemoembolization had higher postoperative 1-year and 3-year risk of death (OR=6.74,4.64,P<0.05).Compared with simple hepatic arterial chemoembolization,thehe combination of hepatic arterial chemoembolization and phase II surgery had a lower 1-year disease progression risk (OR=0.46),but there was no significant difference(P>0.05).The disease progression risk continued to decrease 2 years after surgery (OR=0.29,P<0.05). Conclusion The long-term efficacy of hepatic arterial chemoembolization combined with two-stage surgery in the treatment for unresectable liver cancer is better than that of hepatic arterial chemoembolization alone,whic can effectively improve patients survival and reduce disease progression rate.

Key words: Advanced liver cancer, Unresectable, Hepatic artery chemoembolization, Second-stage surgery

CLC Number: